tag:blogger.com,1999:blog-28269263.post7580406570821480182..comments2023-11-24T19:55:22.871-05:00Comments on PHARMA MARKETING EXPERT WITNESS.: Schering-Plough and Merck in panic: Another Vytorin trial delayed.Unknownnoreply@blogger.comBlogger2125tag:blogger.com,1999:blog-28269263.post-90799590504618384422008-03-30T21:25:00.000-04:002008-03-30T21:25:00.000-04:00I realize that you are aiming for effect with your...I realize that you are aiming for effect with your piece, but the vytorin patent doesn't expire in 2013. Check another source, it will not be available as a generic in the US until ~2017.Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-28269263.post-45880329331343207312008-03-29T16:36:00.000-04:002008-03-29T16:36:00.000-04:00Note also:"An independent Data Monitoring Committe...Note also:<BR/><BR/>"An independent Data Monitoring Committee is evaluating the trial results periodically in an unblinded fashion and could recommend earlier cessation if a definitive excess of benefit or harm were found. At their last evaluation, held on February 18, 2008, the Data Monitoring Committee advised that it found no indication in the data of adverse safety signals that would warrant a change in the protocol, and recommended that the study be continued."<BR/><BR/>Translation: no significant difference between the two arms. <BR/><BR/>MarilynUnknownhttps://www.blogger.com/profile/16193362190826548025noreply@blogger.com